Adipotide

Adipotide Product Introduction

Overview Mechanism of Action

Targeted vascular homing: The sequence CKGGRAKDC (with a disulfide‑closed ring) preferentially binds prohibitin on the endothelium of white adipose tissue vessels, providing adipose‑selective accumulation.

Receptor‑mediated internalization: Binding triggers endocytosis and trafficking to mitochondria.

Mitochondrial disruption: The effector (KLAKLAK)₂ adopts an amphipathic helix, inserts into the mitochondrial membrane, and induces cytochrome c release and caspase‑dependent apoptosis.

Vascular collapse and fat loss: Apoptotic endothelial cells are cleared, adipose perfusion falls, and adipocytes undergo stress/apoptosis, leading to a net reduction in fat mass6.

Key Research Findings

In a study of obese rhesus monkeys, daily subcutaneous administration for 4 weeks led to an average 11% reduction in body weight and ~39% reduction in fat mass, alongside improved insulin sensitivity (insulin use ~60% lower than baseline). These data were published in Science Translational Medicine (2011) and highlighted a primate‑relevant pathway for selective fat reduction distinct from appetite or fat‑absorption modulationResearch Applications and Safety

Applications:

Vascular targeting and anti‑angiogenic mechanism studies

White adipose tissue biology and body composition research

Metabolic consequence analysis (e.g., insulin sensitivity) in preclinical obesity models

Safety and handling:

For laboratory research only; not for human or animal consumption

Observe institutional biosafety and ethical guidelines; use appropriate PPE and aseptic techniques

Note on adverse effects: Preclinical primate studies reported dehydration and kidney lesions at certain doses; these findings underscore the importance of dose‑response evaluation and are not indicative of humanty or efficacy